Evidence map›Paper›PMID 42178778›Full record

Trial reportBritish journal of haematology2026

A multicentre randomized open-label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia.

Haoyi Wang, Ruting Wang, Chenglu Yuan, Kehong Bi, Taiwu Xiao, Qingliang Teng, Haiying Wang, Jie Yu, Ming Hou, Yu Hou

Abstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Haoyi WangDepartment of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, China.
Ruting WangDepartment of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, China.
Chenglu YuanDepartment of Hematology, Qilu Hospital of Shandong University, Shandong University, Qingdao, China.
Kehong BiDepartment of Hematology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China.
Taiwu XiaoDepartment of Hematology, Liaocheng People's Hospital, Liaocheng, China.
Qingliang TengDepartment of Hematology, Tai'an Central Hospital, Tai'an, China.
Haiying WangDepartment of Hematology, The First Affiliated Hospital of Weifang Medical University, Weifang, China.
Jie YuDepartment of Hematology, Weihai Municipal Hospital, Weihai, China.
Ming HouDepartment of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, China.
Yu HouDepartment of Hematology, Qilu Hospital of Shandong University, Shandong University, Jinan, China.

Funding

Distinguished Young and Middle-aged Scholar Foundation of Shandong UniversityECCM Program of Clinical Research Center of Shandong University 2021SDUCRCB009Major Fundamental Research Project of Shandong Province ZR2024ZD44National Natural Science Foundation of China 82270131National Natural Science Foundation of China 82322003National Natural Science Foundation of China 82370131National Natural Science Foundation of China 82500175Natural Science Foundation of Shandong Province ZR2025QC2014Z
6 · The paper itself

Abstract

Standard first-line therapy with dexamethasone requires further optimization due to unsatisfying long-term outcomes in patients with primary immune thrombocytopenia (ITP). Previous research suggested that glycyrrhizinate induces platelet responses in ITP murine models. This study aimed to compare the efficacy and safety of dexamethasone plus glycyrrhizinate with dexamethasone in patients with newly diagnosed ITP. Eligible patients aged ≥18 years with newly diagnosed, treatment-naïve ITP who had baseline platelet count of <30 × 10

Indexed as

DexamethasoneGlycyrrhizic AcidPurpura, Thrombocytopenic, IdiopathicAdultAgedDrug Therapy, CombinationFemaleHumansMaleMiddle AgedPlatelet CountTreatment OutcomeYoung AdultDexamethasoneGlycyrrhizic Acidfirst‐line treatmentglycyrrhizinatehigh‐dose dexamethasonenewly diagnosedprimary immune thrombocytopenia (ITP)

Identifiers

PMID42178778
PMCPMC13462182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.